Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 1 | — | — | — | 1 |
Sarcoma | D012509 | — | — | 1 | 1 | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | 1 | 1 | — | — | — | 1 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | 1 | — | — | — | 1 |
Anaplastic thyroid carcinoma | D065646 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Surufatinib |
INN | surufatinib |
Description | Surufatinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target fibroblast growth factor receptor 1 and vascular endothelial growth factor receptor 2. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1 |
PDB | — |
CAS-ID | 1308672-74-3 |
RxCUI | — |
ChEMBL ID | CHEMBL4297190 |
ChEBI ID | — |
PubChem CID | 52920501 |
DrugBank | DB15106 |
UNII ID | B2K5L1L8S9 (ChemIDplus, GSRS) |